Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

MediXall (MDXL) EBITDA Margin (2021 - 2024)

MediXall's EBITDA Margin history spans 4 years, with the latest figure at 678.92% for Q3 2024.

  • For Q3 2024, EBITDA Margin rose 206454.0% year-over-year to 678.92%; the TTM value through Sep 2024 reached 710.77%, up 136919.0%, while the annual FY2023 figure was 1474.82%, 389499.0% down from the prior year.
  • EBITDA Margin reached 678.92% in Q3 2024 per MDXL's latest filing, up from 919.51% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 678.92% in Q3 2024 to a low of 40730.69% in Q1 2021.
  • Average EBITDA Margin over 4 years is 11366.44%, with a median of 1568.71% recorded in 2023.
  • The largest YoY upside for EBITDA Margin was 3165226bps in 2022 against a maximum downside of -1401586bps in 2022.
  • A 4-year view of EBITDA Margin shows it stood at 25866.33% in 2021, then surged by 66bps to 8805.22% in 2022, then surged by 83bps to 1539.17% in 2023, then skyrocketed by 144bps to 678.92% in 2024.
  • Per Business Quant, the three most recent readings for MDXL's EBITDA Margin are 678.92% (Q3 2024), 919.51% (Q2 2024), and 411.88% (Q1 2024).